Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VM202 in chronic refractory myocardial ischemia
NCT01002495Phase 2Withdrawn
- Sponsor
- Helixmith
- Start
- Mar 2015
- Primary completion
- Jul 2015
- Modality
- Gene Editing, Gene Silencing, Plasmid DNA
- Countries
- 1
01
Overview
A Phase 2 trial of Engensis in Myocardial ischemia (MI), sponsored by Helixmith. Planned start Mar 2015; status: withdrawn.
02
Drugs
Engensis
03
Conditions
Myocardial ischemia (MI)
Beyond the preview
Go deeper on NCT01002495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01002495.